2025 annual financial data
Alnylam Pharmaceuticals 2025 Operating margin
Direct answer
Operating margin was 13.51%.
Operating income was 501.58M USD and net income was 313.75M USD.
Operating cash flow was 524.08M USD.
Get free Alnylam Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3.71B USD
- Operating income
- 501.58M USD
- Net income
- 313.75M USD
- Operating cash flow
- 524.08M USD